Two recent patent cases have engendered considerable uncertainty regarding the ability of biotechnology and pharmaceutical companies to patent their commercial products and methods. The first case, Mayo Collaborative Services v. Prometheus Labs., Inc., relates to the patent eligibility of certain diagnostic methods. On March 20th, the U.S. Supreme Court unanimously ruled that the personalized medicine … Continue reading “Mayo and Myriad: Can Two Patent Rulings Chill Innovation?”
Author: Michael Belliveau
Michael Belliveau has been at Clark+Elbing, a Boston patent prosecution firm, since 1998 and a partner since 2006. His work includes the preparation of patentability, non-infringement, and freedom-to-operate opinions.
Michael works with clients to protect innovations related to small molecule therapeutics for the treatment of bacterial and fungal infections, cancer, neurological disorders, and inflammation. His other areas of focus include drug discovery, molecular diagnostics, DNA and protein chip-based technologies, stem cells, and human gene therapy. He also performs patent due diligence analyses for venture capital investors.
Michael's doctoral research at Harvard University employed cellular and molecular techniques, confocal microscopy, and fluorescence-activated cell sorting to study neural progenitor cell specification and differentiation.